恩替卡韦联合复方肝欣合剂治疗失代偿期乙型肝炎肝硬化临床研究  

Clinical efficacy of entecavir combined with Ganxin mixture on patients at decompensation stage of hepatic cirrhosis

作　　者：苏立稳[1] 赵凯丰[1] 王国华[1] 

机构地区：[1]中国人民解放军第四六四医院消化科,天津300381

出　　处：《中西医结合肝病杂志》2013年第2期86-87,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:观察恩替卡韦(ETV)联合中药复方肝欣合剂治疗失代偿期乙型肝炎肝硬化的临床疗效。方法:将我院2008年10月-2012年10月收治的失代偿期乙型肝炎肝硬化患者80例,分为对照组和治疗组,各40例。对照组患者综合治疗并口服ETV 0.5 mg/次,1次/d,治疗组患者在对治疗组的基础上加服中药复方肝欣合剂,1剂/d,分2次服用。疗程半年。观察治疗前、后患者肝功能、HBV DNA定量水平、Child-Pugh评分变化情况。结果:与对照组比较,治疗组患者的肝功能明显改善,HBV DNA的转阴率、Child-Pugh评分降低均优于对照组(P<0.05)。结论:ETV联合中药复方肝欣合剂对失代偿期乙型肝炎肝硬化患者疗效显著,能改善肝功能,控制HBV复制,降低Child-Pugh评分。Objective：To investigate the effect of entecavir （ETV） combined with Ganxin mixture on patients at decompensation stage of hepatic cirrhosis. Methods： A total of 80 cases were randomly divided into control group and treatment group with 40 cases per group. The control group received comprehensive therapy and ETV 0.5 mg/d, once a day, while the treatment was treated with ETV 0.5 mg/d, once a day and Gan xin mixture twice a day with for half a year besides the comprehensive therapy. Liver function, quantitative level of HBV DNA and Child-Pugh scale was were assessed before and after treatment. Results： Compared with control group, the liver function was improved, HBV was inhibited and score of Child-Pugh scale was decreased in treatment group （P〈0.05） . Conclusion： Combined therapy of ETV and Ganxin mixture is effective on patients at decompensation stage of hepatic cirrhosis. It can improve liver function, control HBV copy （P〉 0.05） and decrease Child-Pugh score,

关 键 词：乙型肝炎 失代偿期肝硬化 恩替卡韦 临床应用 复方肝欣合剂 临床应用 

分 类 号：R575.2[医药卫生—消化系统]